Taxotere® (docetaxel) receives 2 new European approvals for treatment of breast cancer
12-Jan-2005
The first granted Taxotere®, in combination with doxorubicin and cyclophosphamide, for the adjuvant treatment of patients with operable node-positive breast cancer.
A second granted Taxotere®, in combination with Herceptin® (trastuzumab), for the treatment of patients with metastatic breast cancer whose tumors over-express the Her2 gene.
The Commission approval is based on the results of two separate large randomized international trials.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.